SERVICES

Biomarker Partnership

IsoPlexis has partnered with industry leaders to reveal true functional biology to accelerate research and medicine

isoplexis-product-suite-desktop
Kite Logo
Blood Data
OVERVIEW
KITE

A collaboration between IsoPlexis and Kite, a Gilead Company, resulted in the publication of clinical data in demonstrating a significant association between the functionality of anti-CD19 CAR-T cell product before treatment and the objective response in patients with non-Hodgkin lymphoma. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy before treatment, as well as to improve both pre-infusion product potency testing and guide cell product optimization. These findings have been published in Blood.

Nektar Logo
OVERVIEW
NEKTAR

IsoPlexis partnered with Nektar Therapeutics in a collaboration focused on further defining the functional impact of NKTR-214 in the clinic, at the single-cell level, with the goal of revealing both mechanism and potential immune correlates with outcome. In a 2020 Nature Communications publication, the collaboration identified mechanisms of immune persistence in solid tumor to overcome tumor-immune challenges.

COLLABORATE WITH US
Interested in a Strategic
Partnership with IsoPlexis?

Use the button below to get in touch with IsoPlexis

isoplexis-product-suite-desktop
Support and Continued Learning
icon-isou-teal-sm@2x
IsoPlexis University

Protocol Training Videos, Manuals, Support Literature

icon-workflow-support-teal-sm@2x
Workflow & Support

Project Guides, Checklists, and Protocols

GET STARTED
Automate Your Entire Workflow With One System